Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
This study is currently recruiting participants.
Verified by University of Medicine and Dentistry New Jersey, October 2008
Sponsors and Collaborators: University of Medicine and Dentistry New Jersey
AVVAA World Healthcare Products, Inc.
Information provided by: University of Medicine and Dentistry New Jersey
ClinicalTrials.gov Identifier: NCT00143819
  Purpose

The purpose of this study is to assess the efficacy of Neuroskin Forte in relieving the symptoms of dry skin in adults with psoriasis or eczema.


Condition Intervention Phase
Psoriasis
Eczema
Drug: Neuroskin Forte
Drug: Placebo Application
Phase II

MedlinePlus related topics: Eczema Psoriasis
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment
Official Title: Double-Blind, Bilateral, Vehicle-Controlled, Randomized Trial of Neuroskin Forte to Relieve Symptoms of Dry Skin

Further study details as provided by University of Medicine and Dentistry New Jersey:

Primary Outcome Measures:
  • Percent improvement from baseline in the Visual Analog Scale (VAS) score for pruritus (itching) at 8 weeks [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Psoriasis ½-body physician global assessment (PGA) improvement of at least 2 levels [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Eczema ½-body investigator global assessment (IGA) improvement of at least 2 levels [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Improvement in target lesion scoring [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]
  • Photography of target lesions [ Time Frame: 8 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: September 2005
Estimated Study Completion Date: December 2007
Estimated Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Active Comparator
bilateral comparison
Drug: Neuroskin Forte
Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
2: Placebo Comparator
bilateral comparison
Drug: Placebo Application
Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks

Detailed Description:

Subjects will apply study drug and placebo sprays 3 times a day to the assigned, randomized sides of the body. They are allowed to continue using prescription medications, but not moisturizers. Assessments will be performed every other week. Total duration of the study is 10 weeks (8 weeks of treatment and a follow-up visit 2 weeks later).

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Must be at least 18 years of age
  • Have psoriasis or eczema on both sides of the body, with a pair of roughly symmetrical bilateral "target" lesions at least 1.5 cm in diameter

Exclusion Criteria

  • Inability to understand the consent form and/or comply with the requirements of this study
  • Use of moisturizers/emollients within 2 days of beginning study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00143819

Contacts
Contact: Irina Lipets, RN, BSN 732-235-5737 lipetsir@umdnj.edu

Locations
United States, New Jersey
UMDNJ Division of Clinical Pharmacology Recruiting
New Brunswick, New Jersey, United States, 08901
Contact: Patricia Hanas     732-235-8063     hanaspw@umdnj.edu    
Sponsors and Collaborators
University of Medicine and Dentistry New Jersey
AVVAA World Healthcare Products, Inc.
Investigators
Principal Investigator: Melissa Magliocco, MD University of Medicine and Dentistry New Jersey
  More Information

Responsible Party: UMDNJ-RWJMS ( Melissa Magliocco, MD )
Study ID Numbers: 5494
Study First Received: August 31, 2005
Last Updated: October 22, 2008
ClinicalTrials.gov Identifier: NCT00143819  
Health Authority: United States: Institutional Review Board

Keywords provided by University of Medicine and Dentistry New Jersey:
psoriasis
dry skin
eczema
atopic dermatitis

Study placed in the following topic categories:
Dermatitis, Atopic
Skin Diseases
Psoriasis
Skin Diseases, Eczematous
Eczema
Skin Diseases, Papulosquamous
Dermatitis

ClinicalTrials.gov processed this record on January 16, 2009